glp-1 startups Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 Baseline, Roche, Intellia, Eli Lilly:

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 52 print issues and online access $199.00 per year only $3.83 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

Blood in stool : Either bright red blood or black, tarry stools, which may indicate gastrointestinal bleeding

Results are different for everyone

Side effects were consistent with other GLP-1sprimarily mild to moderate gastrointestinal symptoms

Their impact on weight loss outcomes and cardiometabolic health has been transformative, and they remain central to both clinical and commercial strategies

Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist that produces weight loss results between semaglutide and retatrutide, with approximately 20-22% average weight loss at the 15 mg dose